Healthcare entity
All 1 tracked stories fall under one category: regulation. Of the tracked stories, 1 of 1 also mention Duchenne muscular dystrophy, the most common co-covered peer. Each story carries 2 original sources on average, compared with 2.3 for the broader beat in this window.
Last mentioned: Jul 31, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: regulation. Of the tracked stories, 1 of 1 also mention Duchenne muscular dystrophy, the most common co-covered peer. Each story carries 2 original sources on average, compared with 2.3 for the broader beat in this window. The 6 average consequence score is above the beat benchmark of 5.9 in the same window. Ron Johnson appears in 1 tracked Healthcare story from March 10, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 39 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Ron Johnson. Shared-story counts are live from our verified record — not editorial picks.
Senator Ron Johnson (R-Wis.) has initiated a formal investigation into the FDA's handling of biologic therapy applications for rare diseases, specifically targeting Duchenne muscular dystrophy. The probe follows a direct consultation with FDA Commissioner Marty Makary regarding perceived regulatory barriers for life-saving treatments.
Ron Johnson is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
